Influenza vaccine market to grow to £4.3 billion by 2025
pharmafile | October 31, 2016 | News story | Sales and Marketing | influenza
GlobalData has released new findings which indicate that the seasonal influenza vaccine market is set to be worth $4.3 billion by 2025 across the seven major markets: US, UK, France, Italy, Germany, Spain and Japan.
This prediction shows a stark development from the $3.1 billion valuation in 2015 and represents a compound annual growth rate of 3.3%; main drivers of this growth are cited to be amendments to UK and US immunisation schedules, in addition to the move from trivalent vaccines – those which defend against two influenza A strains and one B strain – to quadrivalent formulations, which protect against two strains of each influenza type. This adoption is to be widespread enough that trivalent vaccines will be almost entirely dropped from the US market, with increasing prevalence in Europe over the next decade.
“For the past few decades, children have not been the focus of season influenza immunisation recommendations in developed nations,” explained Christopher J. Pace, GlobalData’s director of Infectious Diseases. “More recently, developed countries such as the US and the UK have issued expanded recommendations for the vaccination of healthy children and adolescents against seasonal influenza, thereby indirectly protecting high-risk groups such as the elderly and the immunocompromised from disease by disrupting community transmission. This generates a significant new opportunity for market penetration.
“Although the vaccination rate across the 7MM is anticipated to remain stable during the next decade,” he continued, “the higher price commanded by quadrivalent vaccines and other next-generation immunisations, such as Sanofi’s Fluzone High-Dose and CSL Limited’s Fluad, is expected to drive market growth.”
Matt Fellows
Related Content
Osivax publishes positive results from trial of influenza vaccine candidate
French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, …
Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine
Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …
Lethal triple mix of winter viruses could “push NHS to breaking point”
A report from the Academy of Medical Sciences has found that a lethal triple mix …
